GM

Globus Medical, Inc.

GMEDHealthcareNASDAQ

Medical Devices · Last scanned Jul 18, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.94B
+16.7% YoY
Net Income
$537.9M
+422.3% YoY
EBITDA
$814.0M
+72.2% YoY
Free Cash Flow
$341.1M

Scan Results

Daily timeframe
3 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 MACD Negative CrossoverHistogram -0.2557, negative momentum
Jul 10 MACD Negative CrossoverHistogram -0.3109, negative momentum
About Globus Medical, Inc.

Headquartered within the healthcare sector, Globus Medical, Inc. focuses on Medical Devices services and products. Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. At a $10.45B market cap, Globus Medical, Inc. ranks as a large-cap company within healthcare. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives.

Key stats
Market Cap$10.45B
P/E (TTM)18.92
Fwd P/E14.95
EPS$4.07
Beta0.95
52W Change+36.7%
ROE13.3%
Analysis

With $629.9M in cash and $115.9M in debt, GMED maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $341.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 13.3%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.02B (2022) to $2.94B (2025), reflecting a 187% increase over the period.

With cash comfortably exceeding debt, GMED has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Globus Medical, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms